MedTrace Logo

ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank

NCT06162546 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-12-08

No results posted yet for this study

Summary

Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired renal function.

The AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank (ARREST-NEPHROSIS) sets out to achieve the following goals, as typical categories of rare disease registries

1. Obtaining real world data on practice patterns and outcomes
2. Networking between affected patients, families, and clinicians.
3. Establish a patient base for facilitated recruitment in studies of drugs, medical devices, and products
4. Development of a Biobank to enable research of potential biomarkers and therapy or disease courses

Conditions

  • Focal Segmental Glomerulosclerosis
  • Proteinuria
  • Nephrotic Syndrome
  • Nephrotic Syndrome Steroid-Resistant

Interventions

OTHER

Registry

Registry Participation, providing data and clinical specimen

Sponsors & Collaborators

  • Christoph Aufricht

    lead OTHER

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2033-12-31
Completion
2033-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06162546 on ClinicalTrials.gov